Expecting therapeutic efficacy improvement, we combined NOTCH3 enhancer inhibition targeting TICs and cytotoxic anti-cancer drugs, such as cis-dichlorodiammineplatinum (CDDP), targeting the proliferating population. This evidence concerns the gene NOTCH3 and cancer.